tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Nail Diseases D009260 2 associated lipids
Paronychia D010304 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyspnea D004417 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Listeriosis D008088 12 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Osteomalacia D010018 5 associated lipids
Tremor D014202 15 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Vasculitis D014657 14 associated lipids
Hypothermia D007035 19 associated lipids
Parkinson Disease D010300 53 associated lipids
Down Syndrome D004314 18 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Graves Disease D006111 6 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Gout D006073 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Biliary Fistula D001658 13 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Neuritis D009443 4 associated lipids
Hypertension, Portal D006975 12 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C D006526 7 associated lipids
Lichen Planus D008010 3 associated lipids
Sclerosis D012598 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Diabetes Complications D048909 4 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Coronary Stenosis D023921 6 associated lipids
Dehydration D003681 11 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Dyslipidemias D050171 7 associated lipids
Fatigue D005221 10 associated lipids
Meningoencephalitis D008590 4 associated lipids
Gynecomastia D006177 6 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Myxedema D009230 2 associated lipids
Pregnancy Complications D011248 19 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Stomatitis D013280 14 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Weight Loss D015431 56 associated lipids
Tinea D014005 5 associated lipids
Critical Illness D016638 13 associated lipids
Endotoxemia D019446 27 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Memory Disorders D008569 33 associated lipids
Glucose Intolerance D018149 13 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Thinness D013851 11 associated lipids
Opportunistic Infections D009894 8 associated lipids
Eczema D004485 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Lupus Nephritis D008181 8 associated lipids
Telangiectasis D013684 2 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Morris-Stiff G et al. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transplant. Proc. pmid:9636525
Claesson K et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. 1998 Transplant. Proc. pmid:9636524
Vanrenterghem Y et al. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. 1998 Transplant. Proc. pmid:9636523
Mendez R FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636522
Morris-Stiff G et al. Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636521
Rostaing L et al. Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. 1998 Transplant. Proc. pmid:9636520
Rostaing L et al. Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. 1998 Transplant. Proc. pmid:9636519
Uchida K et al. Decreasing pancreatic toxicity of tacrolimus by dosage reduction. 1998 Transplant. Proc. pmid:9636518
Sato S et al. Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. 1998 Transplant. Proc. pmid:9636517
Christiaans M et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. 1998 Transplant. Proc. pmid:9636516
van Duijnhoven E et al. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. 1998 Transplant. Proc. pmid:9636515
van Duijnhoven E et al. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. 1998 Transplant. Proc. pmid:9636514
Manzanares C et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. 1998 Transplant. Proc. pmid:9636513
Undre NA and Schäfer A Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. 1998 Transplant. Proc. pmid:9636512
Jordan ML et al. Tacrolimus for rescue of refractory renal allograft rejection. 1998 Transplant. Proc. pmid:9636511
Copley JB et al. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. 1998 Transplant. Proc. pmid:9636510
Kliem V et al. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. 1998 Transplant. Proc. pmid:9636509
Loss GE et al. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. 1998 Transplant. Proc. pmid:9636508
Busque S et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. 1998 Transplant. Proc. pmid:9636507
Morris-Stiff G et al. Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report. 1998 Transplant. Proc. pmid:9636506
Fernando ON et al. Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. 1998 Transplant. Proc. pmid:9636505
Friemann S et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. 1998 Transplant. Proc. pmid:9636504
Budde K et al. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998 Transplant. Proc. pmid:9636503
Carl S et al. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept. 1998 Transplant. Proc. pmid:9636502
Turner CD et al. Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. 1998 Transplant. Proc. pmid:9636501
Eghtesad B et al. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics. 1998 Transplant. Proc. pmid:9636500
Morris-Stiff G et al. Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636499
Kinukawa T et al. Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. 1998 Transplant. Proc. pmid:9636498
Tanabe K et al. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience. 1998 Transplant. Proc. pmid:9636497
Braun F et al. Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. 1998 Transplant. Proc. pmid:9636496
Takahashi K et al. Tacrolimus therapy for ABO-incompatible kidney transplantation. 1998 Transplant. Proc. pmid:9636495
Jensik SC Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636494
Preston R et al. FK 506 as primary immunosuppressive therapy in renal transplantation. 1998 Transplant. Proc. pmid:9636493
Miura S et al. Effect of tacrolimus on the outcome of renal transplantation with donor-specific blood transfusion. 1998 Transplant. Proc. pmid:9636492
Fritsche L et al. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. 1998 Transplant. Proc. pmid:9636481
Marcus N et al. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. 1998 Transplant. Proc. pmid:9636460
Stempfle HU et al. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. 1998 Transplant. Proc. pmid:9636459
Walker RE et al. Clinical outcomes associated with conversion to tacrolimus-based immunosuppression in pediatric cardiac transplantation. 1998 Transplant. Proc. pmid:9636452
Undre NA et al. Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients. 1998 Transplant. Proc. pmid:9636451
Rieber J et al. Effects of tacrolimus and cyclosporine on the coronary microcirculation after heart transplantation: a prospective study with serial intracoronary flow measurements. 1998 Transplant. Proc. pmid:9636446
Kobashigawa JA Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine. 1998 Transplant. Proc. pmid:9636445
Miki T et al. Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. 1998 Transplant. Proc. pmid:9636444
Li S et al. Intrathymic inoculation of donor bone marrow at the time of transplantation plus a short course of tacrolimus induce long-term acceptance to rat lung allografts. 1998 Transplant. Proc. pmid:9636431
Chen H et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9636419
Yura H et al. Development of a macromolecular prodrug of FK 506: II: In vitro study for FK 506-dextran conjugate. 1998 Transplant. Proc. pmid:9636416
Yoshimura N et al. Development of a macromolecular prodrug of FK 506: III: In vivo disposition of FK 506-dextran conjugate. 1998 Transplant. Proc. pmid:9636415
Fujimura T et al. Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636413
Isobe M et al. Downregulation of endothelin expression in allograft coronary arteries after gene therapy targeting Cdk2 kinase. 1998 Transplant. Proc. pmid:9636407
McAlister VC Liposomal tacrolimus: drug migration within blood compartments. 1998 Transplant. Proc. pmid:9636404
Krüger B et al. Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. 1998 Transplant. Proc. pmid:9636399
Silber RE et al. Comparison of the effect of FK 506 and alpha/beta-T-cell antibody R73 on transplant vascular sclerosis after heterotopic rat heart transplantation. 1998 Transplant. Proc. pmid:9636398
Müller V et al. Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. 1998 Transplant. Proc. pmid:9636396
Hutchinson IV et al. Differences in the mode of action of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636388
Ginevri F et al. Expression of collagen by renal fibroblasts treated with FK 506 in vitro. 1998 Transplant. Proc. pmid:9636387
Nicholson ML et al. Is TGF-beta a profibrotic cytokine in human renal transplants? 1998 Transplant. Proc. pmid:9636384
Tredger JM et al. Therapeutic monitoring of tacrolimus (FK506) with the first- and second-generation microparticle enzyme immunoassays: performance and results in four patient populations. 1998 Ther Drug Monit pmid:9631923
Al-Awwa IA et al. Importance of allograft biopsy in renal transplant recipients: correlation between clinical and histological diagnosis. 1998 Am. J. Kidney Dis. pmid:9631859
Starzl TE et al. Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. 1998 Am. J. Kidney Dis. pmid:9631858
Ellouk-Achard S et al. FK506 (Tacrolimus) decreases the cytotoxicity of cyclosporin A in rat hepatocytes in primary culture: implication of CYP3A induction. 1998 Arch. Toxicol. pmid:9630010
Takada Y et al. Prolonged hepatic warm ischemia in non-heart-beating donors: protective effects of FK506 and a platelet activating factor antagonist in porcine liver transplantation. 1998 Surgery pmid:9626320
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Schulman SL et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. 1998 Transplantation pmid:9625026
Lampen A et al. Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. 1998 Xenobiotica pmid:9622846
Kikuchi M et al. Protective effects of FK506 against glutamate-induced neurotoxicity in retinal cell culture. 1998 Invest. Ophthalmol. Vis. Sci. pmid:9620083
Idilman R et al. Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant. 1998 Eur J Gastroenterol Hepatol pmid:9619393
Tomás ML [Immunosuppressive agents: side effects]. 1997 An R Acad Nac Med (Madr) pmid:9616947
Samsó M and Wagenknecht T Contributions of electron microscopy and single-particle techniques to the determination of the ryanodine receptor three-dimensional structure. 1998 J. Struct. Biol. pmid:9615436
Kliem V and Brunkhorst R Tacrolimus in kidney transplantation. A clinical review. 1998 Nephron pmid:9609456
Ito H et al. Myoblast transplantation in non-dystrophic dog. 1998 Neuromuscul. Disord. pmid:9608563
Singer NG and McCune WJ Update on immunosuppressive therapy. 1998 Curr Opin Rheumatol pmid:9608317
Tomono M et al. Inhibitors of calcineurin block expression of cyclins A and E induced by fibroblast growth factor in Swiss 3T3 fibroblasts. 1998 Arch. Biochem. Biophys. pmid:9606972
Tomura N et al. Transient neurotoxicity associated with FK506: MR findings. 1998 May-Jun J Comput Assist Tomogr pmid:9606397
Homey B et al. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. 1998 J. Immunol. pmid:9605132
Chang RK et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. 1998 Am. J. Cardiol. pmid:9604971
Capone D et al. Therapeutic monitoring of tacrolimus in pediatric and adult transplanted patients. 1998 J Chemother pmid:9603651
Shapiro R et al. Alopecia as a consequence of tacrolimus therapy. 1998 Transplantation pmid:9603186
Beatty PR et al. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. 1998 Transplantation pmid:9603175
Jurcevic S et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. 1998 Transplantation pmid:9603168
Oyanagui Y Immunosuppressants enhance superoxide radical/nitric oxide-dependent dexamethasone suppression of ischemic paw edema in mice. 1998 Eur. J. Pharmacol. pmid:9600660
Hueros G et al. A maize FK506-sensitive immunophilin, mzFKBP-66, is a peptidylproline cis-trans-isomerase that interacts with calmodulin and a 36-kDa cytoplasmic protein. 1998 Planta pmid:9599809
Wagner R et al. 32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency. 1998 J. Med. Chem. pmid:9599228
Koyama T et al. [Effects of various drugs on IL-8 production by eosinophils collected from patients with allergic inflammation]. 1998 Jpn J Antibiot pmid:9597507
Gregory CR Immunosuppressive approaches to the prevention of graft vascular disease. 1998 Transplant. Proc. pmid:9595134
Weis M et al. Impact of immunosuppression on coronary endothelial function after cardiac transplantation. 1998 Transplant. Proc. pmid:9595131
Marone G et al. Immunopharmacology of human mast cells and basophils. 1998 Int. J. Clin. Lab. Res. pmid:9594358
Wakita H et al. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. 1998 Brain Res. pmid:9593846
Hebebrand D et al. Limb xenotransplantation using FK506 and RS61443 immunosuppression. 1998 J Reconstr Microsurg pmid:9590615
Chiba K et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. 1998 J. Immunol. pmid:9590253
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Muraki T et al. Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. 1998 Transplantation pmid:9583878
Zervos XA et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplantation pmid:9583863
Abu-Elmagd K et al. Clinical intestinal transplantation: new perspectives and immunologic considerations. 1998 J. Am. Coll. Surg. pmid:9583691
Cardoso CM et al. Uncoupling of Ca2+ transport ATPase in muscle and blood platelets by diacylglycerol analogues and cyclosporin A antagonism. 1997 Biochem. J. pmid:9581558
Sugi-Ikai N et al. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease. 1998 Invest. Ophthalmol. Vis. Sci. pmid:9579479
Sakane T [Physiopathology and therapy of Behcet's syndrome]. 1998 Nippon Naika Gakkai Zasshi pmid:9577569
Miyasaka N [Recent findings on etiological mechanism of autoimmune diseases]. 1998 Nippon Naika Gakkai Zasshi pmid:9577564
Barinaga M Signaling path may lead to better heart-failure therapies. 1998 Science pmid:9575084
Matsuda T et al. Involvement of calcineurin in Ca2+ paradox-like injury of cultured rat astrocytes. 1998 J. Neurochem. pmid:9572286
Finney NS Enantioselective epoxide hydrolysis: catalysis involving microbes, mammals and metals. 1998 Chem. Biol. pmid:9571210
Araki T et al. Post-ischemic alterations in [3H]FK506 binding in the gerbil and rat brains. 1998 Metab Brain Dis pmid:9570636